Evidence map›Paper›PMID 42225068›Full record

ArticleCell reports methods2026

Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens.

Silvia Fenoglio, Yi Yu, James Tepper, Lauren Grove, Alborz Bejnood, Samuel R Meier, Ashley H Choi, Hsin-Jung Wu, Annabel Devault, Shangtao Liu and 13 more

Abstract read
In one paragraph

Article in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Silvia FenoglioTango Therapeutics Inc, Boston, MA, USA.
Yi YuTango Therapeutics Inc, Boston, MA, USA.
James TepperTango Therapeutics Inc, Boston, MA, USA.
Lauren GroveTango Therapeutics Inc, Boston, MA, USA.
Alborz BejnoodTango Therapeutics Inc, Boston, MA, USA.
Samuel R MeierTango Therapeutics Inc, Boston, MA, USA.
Ashley H ChoiTango Therapeutics Inc, Boston, MA, USA.
Hsin-Jung WuTango Therapeutics Inc, Boston, MA, USA.
Annabel DevaultTango Therapeutics Inc, Boston, MA, USA.
Shangtao LiuTango Therapeutics Inc, Boston, MA, USA.
Binzhang ShenTango Therapeutics Inc, Boston, MA, USA.
Tenzing KhenduTango Therapeutics Inc, Boston, MA, USA.
Hannah StoweTango Therapeutics Inc, Boston, MA, USA.
Esther C H UijttewaalInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Dr. Bohr-Gasse 3, Vienna BioCenter (VBC), Vienna, Austria.
Minjie ZhangTango Therapeutics Inc, Boston, MA, USA.
Brian B HainesTango Therapeutics Inc, Boston, MA, USA.
Erik WilkerTango Therapeutics Inc, Boston, MA, USA.
Alan HuangTango Therapeutics Inc, Boston, MA, USA.
Daniel SchramekCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Ulrich EllingInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Dr. Bohr-Gasse 3, Vienna BioCenter (VBC), Vienna, Austria.
Xuewen PanTango Therapeutics Inc, Boston, MA, USA.
Jannik N AndersenTango Therapeutics Inc, Boston, MA, USA.
Teng TengTango Therapeutics Inc, Boston, MA, USA. Electronic address: tteng@tangotx.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR-StAR (stochastic activation by recombination) is an inducible pooled screening system that activates gene knockout after tumor engraftment and provides matched internal controls for guide-level normalization. In this study, we explore the scalability and reproducibility of this approach for in vivo cancer screens. Through barcode-embedded sequencing and the development of a Bayesian analysis pipeline, we screened a 30,000-sgRNA library in A549 xenografts, achieving reproducible dropout and enrichment phenotypes using just ∼30 tumors. Across additional xenograft models, single tumors yielded reliable functional annotation for ∼1,000 genes. Comparing in vivo and in vitro screens uncovered tumor suppressor effects detectable only in vivo; for example, KMT2C and KMT2D knockouts produced contrasting growth and transcriptional programs. Together with our R analysis package, we show that CRISPR-StAR enables scalable in vivo dependency mapping that complements in vitro resources and reduces animal use by up to 7-fold versus conventional dropout screens, improving methodological rigor at genome-scale clonal resolution.

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsGene LibraryRNA, Guide, CRISPR-Cas SystemsAnimalsCell Line, TumorHumansMiceReproducibility of ResultsRNA, Guide, CRISPR-Cas Systemsclonal barcodeCP: cancer biologyCP: geneticsCRISPR screenCRISPR-StARfunctional genomicsin vivo screenKMT2CKMT2Dtumor microenvironmentUMIUMIBB

Identifiers

PMID42225068
PMCPMC13390110

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.